nach oben

Clinical Rheumatology

Erschienen in:

15.02.2020 | Review Article

At the crossroads of gout and psoriatic arthritis: “psout”

verfasst von: Renaud Felten, Pierre-Marie Duret, Jacques-Eric Gottenberg, Lionel Spielmann, Laurent Messer

Erschienen in: Clinical Rheumatology | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Psoriatic arthritis and gout are frequently encountered conditions sharing a number of common risk factors, which render their independent study difficult. Epidemiological studies have demonstrated a strong link between these diseases, suggesting the presence of underlying, intertwined pathophysiological mechanisms that currently remain unknown. Indeed, sodium urate crystals could play a pathogenic role in psoriasis and psoriatic arthritis. In daily practice, the distinction between psoriatic arthritis associated with hyperuricemia and a gouty arthropathy with psoriasis is complex. Several common pathogenic features suggest a more intricate relationship than their mere coexistence in the same patient. Thus, the concurrence of these two diseases should be seen as a novel overlap syndrome, at the boundary between inflammatory and metabolic rheumatism. The present update aims to clarify the determinants of the link and to define this new nosological entity. Its recognition could have therapeutic implications that appear essential for treatment optimization in a personalized setting.

Key Points

• What is already known about this subject? Psoriatic arthritis (PsA) and gout have strong interconnections, including comorbidities and pathophysiology. One must note that confounding clinical symptoms and radiological signs of PsA and gout are similar and difficult to differentiate in patients whose radiological lesions become too advanced to be differentiated or with less clearly defined phenotypes.

• What does this study add? The pathogenic role of chronic hyperuricemia in the development and maintenance of PsA is based on epidemiological, clinical, and fundamental arguments and hence does not appear fortuitous. These two pathological processes can influence each other.

• How might this impact on clinical practice? This new line of thinking regarding the convergence of gout and PsA, involving the role of urate crystals, could prompt a potential new approach to treatment (urate-lowering therapy) among patients with active/refractory PsA.

Eisen AZ, Seegmiller JE (1961) Uric acid metabolism in psoriasis. J Clin Invest 40:1486–1494. https://doi.org/10.1172/JCI104379 CrossRefPubMedPubMedCentral

Lea WA, Curtis AC, Bernstein IA (1958) Serum uric acid levels in psoriasis. J Invest Dermatol 31:269–271CrossRef

Zimmer JG, Demis DJ (1966) Associations between gout, psoriasis, and sarcoidosis with consideration of their pathogenic significance. Ann Intern Med 64:786–796CrossRef

Pokorný M, Resl V (1968) Psoriasis and factors affecting the level of uricaemia. Acta Univ Carol Med (Praha) 14:71–74

Lambert JR, Wright V (1977) Serum uric acid levels in psoriatic arthritis. Ann Rheum Dis 36:264–267. https://doi.org/10.1136/ard.36.3.264 CrossRefPubMedPubMedCentral

Ogdie A, Schwartzman S, Husni ME (2015) Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol 27:118–126. https://doi.org/10.1097/BOR.0000000000000152 CrossRefPubMed

Kuo C-F, Grainge MJ, Mallen C, Zhang W, Doherty M (2016) Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann Rheum Dis 75:210–217. https://doi.org/10.1136/annrheumdis-2014-206410 CrossRefPubMed

Brenner W, Gschnait F (1978) Serum uric acid levels in untreated and PUVA-treated patients with psoriasis. Dermatologica 157:91–95CrossRef

Gschnait F, Ita E (1978) Serum uric levels in patients with psoriasis vulgaris (author’s transl). Wien Klin Wochenschr 90:309–311PubMed

10.

Gisondi P, Targher G, Cagalli A, Girolomoni G (2014) Hyperuricemia in patients with chronic plaque psoriasis. J Am Acad Dermatol 70:127–130. https://doi.org/10.1016/j.jaad.2013.09.005 CrossRefPubMed

11.

Burnett JW (1982) Acute gout secondary to psoriasis exacerbated by photochemotherapy. Arch Dermatol 118:211CrossRef

12.

Fordham JN, Storey GO (1982) Psoriasis and gout. Postgrad Med J 58:477–480CrossRef

13.

Liu M, Li J-H, Li B, He CD, Xiao T, Chen HD (2009) Coexisting gout, erythrodermic psoriasis and psoriatic arthritis. Eur J Dermatol 19:184–185. https://doi.org/10.1684/ejd.2008.0607 CrossRefPubMed

14.

Lobato LC, Coutinho JC, Frota MZM, Schettini AP, Santos M (2017) Chronic tophaceous gout in patients with psoriasis. An Bras Dermatol 92:104–106. https://doi.org/10.1590/abd1806-4841.20174895 CrossRefPubMedPubMedCentral

15.

Venkatasubramaniam KV, Bluhm GB, Riddle JM (1980) Psoriatic arthropathy and crystal-induced synovitis. J Rheumatol 7:213–217PubMed

16.

De Bari C, Lapadula G, Cantatore FP (1998) Coexisting psoriatic arthritis, gout, and chondrocalcinosis. Scand J Rheumatol 27:306–309CrossRef

17.

López-Reyes A, Hernández-Díaz C, Hofmann F, Pineda C (2012) Gout mimicking psoriatic arthritis flare. J Clin Rheumatol 18:220. https://doi.org/10.1097/RHU.0b013e318259aa2e CrossRefPubMed

18.

Morasiewicz P, Koprowski P, Dragan S (2014) Coexisting psoriasis,psoriatic arthritis, gout and Dupuytren’s contracture. Ortop Traumatol Rehabil 16:441–447. https://doi.org/10.5604/15093492.1119622 CrossRefPubMed

19.

Bosmansky K, Trnavsky K (1983) Psoriasis and gout: report of 4 cases. Clin Rheumatol 2:423–426CrossRef

20.

Merola JF, Wu S, Han J, Choi HK, Qureshi AA (2015) Psoriasis, psoriatic arthritis, and risk of gout in U.S. men and women. Ann Rheum Dis 74:1495–1500. https://doi.org/10.1136/annrheumdis-2014-205212 CrossRefPubMed

21.

Tsuruta N, Imafuku S, Narisawa Y (2017) Hyperuricemia is an independent risk factor for psoriatic arthritis in psoriatic patients. J Dermatol. https://doi.org/10.1111/1346-8138.13968

22.

Hu SC-S, Lin C-L, Tu H-P (2019) Association between psoriasis, psoriatic arthritis and gout: a nationwide population-based study. J Eur Acad Dermatol Venereol JEADV 33:560–567. https://doi.org/10.1111/jdv.15290 CrossRefPubMed

23.

AlJohani R, Polachek A, Ye JY et al (2018) Characteristic and outcome of psoriatic arthritis patients with hyperuricemia. J Rheumatol 45:213–217. https://doi.org/10.3899/jrheum.170384 CrossRefPubMed

24.

Golov KG, Ivanov OL, Balkarov IM, Novoselov VS (1994) Clinical significance of hyperuricemia in psoriasis. Klin Med (Mosk) 72:34–36

25.

Martinon F, Pétrilli V, Mayor A et al (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237–241. https://doi.org/10.1038/nature04516 CrossRefPubMed

26.

Desai J, Kumar SV, Mulay SR et al (2016) PMA and crystal-induced neutrophil extracellular trap formation involves RIPK1-RIPK3-MLKL signaling. Eur J Immunol 46:223–229. https://doi.org/10.1002/eji.201545605 CrossRefPubMed

27.

Schauer C, Janko C, Munoz LE, Zhao Y, Kienhöfer D, Frey B, Lell M, Manger B, Rech J, Naschberger E, Holmdahl R, Krenn V, Harrer T, Jeremic I, Bilyy R, Schett G, Hoffmann M, Herrmann M (2014) Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat Med 20:511–517. https://doi.org/10.1038/nm.3547 CrossRefPubMed

28.

Uratsuji H, Tada Y, Kawashima T et al (2012) P2Y6 receptor signaling pathway mediates inflammatory responses induced by monosodium urate crystals. J Immunol 188:436–444. https://doi.org/10.4049/jimmunol.1003746 CrossRefPubMed

29.

Chen DP, Wong CK, Tam LS, Li EK, Lam CW (2011) Activation of human fibroblast-like synoviocytes by uric acid crystals in rheumatoid arthritis. Cell Mol Immunol 8:469–478. https://doi.org/10.1038/cmi.2011.35 CrossRefPubMedPubMedCentral

30.

Choe J-Y, Kim S-K (2015) Association between serum uric acid and inflammation in rheumatoid arthritis: perspective on lowering serum uric acid of leflunomide. Clin Chim Acta Int J Clin Chem 438:29–34. https://doi.org/10.1016/j.cca.2014.07.039 CrossRef

31.

Chhana A, Callon KE, Pool B, Naot D, Watson M, Gamble GD, McQueen F, Cornish J, Dalbeth N (2011) Monosodium urate monohydrate crystals inhibit osteoblast viability and function: implications for development of bone erosion in gout. Ann Rheum Dis 70:1684–1691. https://doi.org/10.1136/ard.2010.144774 CrossRefPubMed

32.

Shi Y, Evans JE, Rock KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425:516–521. https://doi.org/10.1038/nature01991 CrossRefPubMed

33.

Eleftheriadis T, Pissas G, Karioti A, Antoniadi G, Golfinopoulos S, Liakopoulos V, Mamara A, Speletas M, Koukoulis G, Stefanidis I (2013) Uric acid induces caspase-1 activation, IL-1β secretion and P2X7 receptor dependent proliferation in primary human lymphocytes. Hippokratia 17:141–145PubMedPubMedCentral

34.

Eleftheriadis T, Pissas G, Sounidaki M, Antoniadi G, Tsialtas I, Liakopoulos V, Stefanidis I (2017) Urate crystals directly activate the T-cell receptor complex and induce T-cell proliferation. Biomed Rep 7:365–369. https://doi.org/10.3892/br.2017.960 CrossRefPubMedPubMedCentral

35.

Conforti-Andreoni C, Spreafico R, Qian HL et al (2011) Uric acid-driven Th17 differentiation requires inflammasome-derived IL-1 and IL-18. J Immunol 187:5842–5850. https://doi.org/10.4049/jimmunol.1101408 CrossRefPubMed

36.

Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, Cao W, Wang YH, Su B, Nestle FO, Zal T, Mellman I, Schröder JM, Liu YJ, Gilliet M (2007) Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449:564–569. https://doi.org/10.1038/nature06116 CrossRefPubMed

37.

Büchau AS, Gallo RL (2007) Innate immunity and antimicrobial defense systems in psoriasis. Clin Dermatol 25:616–624. https://doi.org/10.1016/j.clindermatol.2007.08.016 CrossRefPubMedPubMedCentral

38.

Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, Bowman EP, Krueger JG (2008) Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 128:1207–1211. https://doi.org/10.1038/sj.jid.5701213 CrossRefPubMed

39.

Goldman M (1981) Uric acid in the etiology of psoriasis. Am J Dermatopathol 3:397–404CrossRef

40.

Li X, Miao X, Wang H, Wang Y, Li F, Yang Q, Cui R, Li B (2016) Association of serum uric acid levels in psoriasis: a systematic review and meta-analysis. Medicine (Baltimore) 95:e3676. https://doi.org/10.1097/MD.0000000000003676 CrossRef

41.

Patience A, Helliwell PS, Siddle HJ (2018) Focussing on the foot in psoriatic arthritis: pathology and management options. Expert Rev Clin Immunol 14:21–28. https://doi.org/10.1080/1744666X.2018.1413351 CrossRefPubMed

42.

Tsai Y-G, Chang D-M, Kuo S-Y, Wang WM, Chen YC, Lai JH (2003) Relationship between human lymphocyte antigen-B27 and clinical features of psoriatic arthritis. J Microbiol Immunol Infect 36:101–104PubMed

43.

López-Larrea C, Torre Alonso JC, Rodriguez Perez A, Coto E (1990) HLA antigens in psoriatic arthritis subtypes of a Spanish population. Ann Rheum Dis 49:318–319CrossRef

44.

Oliviero F, Scanu A, Galozzi P et al (2013) Prevalence of calcium pyrophosphate and monosodium urate crystals in synovial fluid of patients with previously diagnosed joint diseases. Joint Bone Spine 80:287–290. https://doi.org/10.1016/j.jbspin.2012.08.006 CrossRefPubMed

45.

Ory PA, Gladman DD, Mease PJ (2005) Psoriatic arthritis and imaging. Ann Rheum Dis 64(Suppl 2):ii55–ii57. https://doi.org/10.1136/ard.2004.033928 CrossRefPubMedPubMedCentral

46.

Lu H, Sheng J, Dai J, Hu X (2017) Tophaceous gout causing lumbar stenosis: a case report. Medicine (Baltimore) 96:e7670. https://doi.org/10.1097/MD.0000000000007670 CrossRef

47.

Chen W, Wang Y, Li Y et al (2017) Gout mimicking spondyloarthritis: case report and literature review. J Pain Res 10:1511–1514. https://doi.org/10.2147/JPR.S133572 CrossRefPubMedPubMedCentral

48.

Dalbeth N, Milligan A, Doyle AJ, Clark B, McQueen F (2012) Characterization of new bone formation in gout: a quantitative site-by-site analysis using plain radiography and computed tomography. Arthritis Res Ther 14:R165. https://doi.org/10.1186/ar3913 CrossRefPubMedPubMedCentral

49.

Gentili A (2006) The advanced imaging of gouty tophi. Curr Rheumatol Rep 8:231–235. https://doi.org/10.1007/s11926-996-0030-6 CrossRefPubMed

50.

Arendse R, Gcelu A, Scott C, Beighton P, Kalla A (2010) Do the radiographic features of joint destruction in tophaceous gout imply a different pathophysiology to that of rheumatoid and psoriatic arthritis? Clin Rheumatol 29:1181–1183. https://doi.org/10.1007/s10067-010-1521-4 CrossRefPubMed

51.

Cortet B, Duquesnoy B, Amoura I et al (1994) Ankylosing gout. Apropos of 2 cases. Rev Rhum Ed Fr 61:49–52PubMed

52.

Gerster JC, Landry M, Rappoport G, Rivier G, Duvoisin B, Schnyder P (1996) Enthesopathy and tendinopathy in gout: computed tomographic assessment. Ann Rheum Dis 55:921–923CrossRef

53.

Bongartz T, Glazebrook KN, Kavros SJ, Murthy NS, Merry SP, Franz WB 3rd, Michet CJ, Veetil BM, Davis JM 3rd, Mason TG 2nd, Warrington KJ, Ytterberg SR, Matteson EL, Crowson CS, Leng S, McCollough C (2015) Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study. Ann Rheum Dis 74:1072–1077. https://doi.org/10.1136/annrheumdis-2013-205095 CrossRefPubMed

54.

Chew N, Cho J (2018) Dual-energy CT for the diagnosis of sacroiliac and spinal gout. Joint Bone Spine. https://doi.org/10.1016/j.jbspin.2018.10.005

55.

Zhu J, Li A, Jia E, Zhou Y, Xu J, Chen S, Huang Y, Xiao X, Li J (2017) Monosodium urate crystal deposition associated with the progress of radiographic grade at the sacroiliac joint in axial SpA: a dual-energy CT study. Arthritis Res Ther 19:83. https://doi.org/10.1186/s13075-017-1286-0 CrossRefPubMedPubMedCentral

56.

O’Connor PJ (2013) Crystal deposition disease and psoriatic arthritis. Semin Musculoskelet Radiol 17:74–79. https://doi.org/10.1055/s-0033-1333940 CrossRefPubMed

57.

Abogamal A (2019) Acute knee arthritis in psoriasis patient: What ultrasound could tell us? Int J Clin Rheumatol 14:160

58.

Duffield SJ, Ellis BM, Goodson N, Walker-Bone K, Conaghan PG, Margham T, Loftis T (2017) The contribution of musculoskeletal disorders in multimorbidity: implications for practice and policy. Best Pract Res Clin Rheumatol 31:129–144. https://doi.org/10.1016/j.berh.2017.09.004 CrossRefPubMed

59.

Schieir O, Tosevski C, Glazier RH, Hogg-Johnson S, Badley EM (2017) Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis. Ann Rheum Dis 76:1396–1404. https://doi.org/10.1136/annrheumdis-2016-210275 CrossRefPubMed

60.

Grassi D, Desideri G, Di Giacomantonio AV et al (2014) Hyperuricemia and cardiovascular risk. High Blood Press Cardiovasc Prev Off J Ital Soc Hypertens 21:235–242. https://doi.org/10.1007/s40292-014-0046-3 CrossRef

61.

Raychaudhuri SP, Wilken R, Sukhov AC, Raychaudhuri SK, Maverakis E (2017) Management of psoriatic arthritis: early diagnosis, monitoring of disease severity and cutting edge therapies. J Autoimmun 76:21–37. https://doi.org/10.1016/j.jaut.2016.10.009 CrossRefPubMed

62.

Arevalo AB, Haddadin F, Contreras G et al (2019) Sat0371 Cardiovascular Impact of Hyperuricemia in Patients with Psoriatic Arthritis. Ann Rheum Dis 78:1268–1268. https://doi.org/10.1136/annrheumdis-2019-eular.1674

63.

Arida D, Silva L, Skare TL (2014) The hypouricemiant effect of leflunomide. Joint Bone Spine 81:273–274. https://doi.org/10.1016/j.jbspin.2013.10.008 CrossRefPubMed

64.

Emery P, Breedveld FC, Lemmel EM et al (2000) A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatol (Oxford) 39:655–665. https://doi.org/10.1093/rheumatology/39.6.655 CrossRef

Titel: At the crossroads of gout and psoriatic arthritis: “psout”
verfasst von: Renaud Felten
Pierre-Marie Duret
Jacques-Eric Gottenberg
Lionel Spielmann
Laurent Messer
Publikationsdatum: 15.02.2020
Verlag: Springer London
Erschienen in: Clinical Rheumatology / Ausgabe 5/2020
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-020-04981-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2020

Effects of rituximab therapy on B cell differentiation and depletion

Incidence of tuberculosis in patients receiving anti-TNF therapy for rheumatic diseases: a systematic review

Relapses in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a retrospective study

Evaluation of cognitive function in systemic sclerosis patients: a pilot study

Clinicopathological factors for tubulointerstitial injury in lupus nephritis